Vimarsana
Biggest News Aggregation in the World

Plasma Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Plasma Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Plasma Cell Today - Breaking & Trending Today

TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma - Vimarsana News

TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma

Published: February 20, 2024

/PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...

Source: prnewswire.com
Related Topics:
United StatesChristie CorbettRachel KobosPrnewswire JohnsonSatu GlaweNational Cancer InstituteEuropean CommissionAmerican Society Of Clinical OncologyExchange CommissionAmerican Cancer SocietyOncology Research DevelopmentOther Administration ReactionsSurveillance Research ProgramJohnson IncJanssen Biotech IncNone Of Janssen Research DevelopmentDrug AdministrationJanssen Research DevelopmentBiologics License ApplicationVice PresidentOncology ResearchJohnson InnovativeRisk EvaluationMitigation StrategyFetal Toxicity
U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma - Vimarsana News

U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

Published: August 10, 2023

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted...

Source: prnewswire.com
Related Topics:
United StatesSan FranciscoMichael AndreiniCaroline PavisObrian KenneyPeter LebowitzExchange CommissionUniversity Of CaliforniaJanssen Pharmaceutical Companies Of JohnsonJanssen Biotech IncMyeloma ProgramEuropean CommissionCompanies Of JohnsonNational Cancer InstituteNone Of The Janssen Pharmaceutical CompaniesEastern Cooperative Oncology GroupJanssen Research DevelopmentSurveillance Research ProgramMyeloma Research FoundationAmerican Cancer SocietyDrug AdministrationJanssen Pharmaceutical CompaniesAjai ChariMultiple Myeloma ProgramClinical Medicine
CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study - Vimarsana News

CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study

Published: June 5, 2023

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that results from the Phase 3 CARTITUDE-4 study showed CARVYKTI®...

Source: prnewswire.com
Related Topics:
United StatesSatu GlaweBinod DhakalHemophagocytic LymphohistiocytosisLegend Biotech United States IncNational Cancer InstituteEuropean CommissionCongress AbstractNone Of Janssen Research DevelopmentExchange CommissionAmerican Cancer SocietyDivision Of HematologyJanssen Biotech IncEuropean Medicines AgencyEuropean Hematology AssociationJanssen Pharmaceutical Companies Of JohnsonJanssen Research DevelopmentCollege Of WisconsinJanssen Pharmaceutical CompaniesAmerican Society Of Clinical OncologyAmerican Society Of Clinical Oncology Annual MeetingCompanies Of JohnsonDrug AdministrationNew England JournalClinical Oncology
Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma - Vimarsana News

Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

Published: June 5, 2023

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term data from the pivotal Phase 1/2 MajesTEC-1 study showing...

Source: prnewswire.com
Related Topics:
Noord HollandUnited StatesRachel KobosSatu GlaweChristie CorbettEastern Cooperative Oncology GroupExchange CommissionNone Of The Janssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonEuropean Medicines AgencyJanssen Pharmaceutical CompaniesEuropean CommissionAmerican Cancer SocietyAmerican Society Of Clinical OncologyNational Comprehensive Cancer NetworkJanssen Research DevelopmentCompanies Of JohnsonInternational Myeloma Working GroupJanssen Oncology Research DevelopmentOther Administration ReactionsNational Cancer InstituteClinical OncologyAnnual MeetingConfidence IntervalNot Evaluable
Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma - Vimarsana News

Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

Published: June 3, 2023

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of...

Source: prnewswire.com
Related Topics:
United StatesChristie CorbettArnob BanerjeeYael CohenSatu GlaweEarly Development OncologyCompanies Of JohnsonJanssen Pharmaceutical Companies Of JohnsonNational Comprehensive Cancer NetworkNone Of The Janssen Pharmaceutical CompaniesAmerican Society Of Clinical OncologyJanssen Biotech IncNational Cancer InstituteAmerican Cancer SocietyJanssen Research DevelopmentExchange CommissionOther Administration ReactionsAviv Sourasky Medical CenterJanssen Pharmaceutical CompaniesEuropean CommissionHematology InstituteEuropean Medicines AgencyClinical OncologyAnnual MeetingMyeloma Unit